Key result
Combined heterozygous FVL and FII 20210A mutation was associated with a higher risk of pregnancy-associated VTE compared to FII mutation alone.
Why the study?
Does combined heterozygous FVL and FII mutation increase the risk of pregnancy-associated VTE compared to FII mutation alone?
Cohort (n=129)
Does combined heterozygous FVL and FII mutation increase the risk of pregnancy-associated VTE compared to FII mutation alone?
Women with combined heterozygous FVL and FII mutations have a significantly higher risk of pregnancy-associated VTE compared to those with FII mutation alone, suggesting a need for targeted prophylaxis.
Answers are grounded in this paper and cite their sources.
May support individualized VTE risk counseling in pregnancy; leaves open whether intensified prophylaxis improves outcomes.
The risk of venous thromboembolism (VTE) in the absence of prophylaxis was evaluated in a retrospective study of 47 women (84 pregnancies) with combined thrombophilia [heterozygous factor V Leiden (FVL) plus prothrombin (FII) 20210A mutation (group I)] and in 82 women (193 pregnancies) with the FII alone (group II). VTE was more frequent in group I than in group II [17.8% versus 6.2%, P = 0.003, relative risk (RR) 2.9, 95% confidence interval (CI) 1.4-5.9], ante partum (7.1% and 2.1%) and post partum (11.5% and 4.2%). The risk was higher in index cases than in family members (RR 2.5, 95% CI 1.2-5.2 and RR 2.1, 95% CI 0.2-22.3 respectively) Even women who had no history of VTE before pregnancy had an increased risk (RR 2.2, 95% CI 1.0-4.8). Our results suggest that, during ante partum, prophylaxis is indicated in women with combined thrombophilia and with a VTE before pregnancy. In those without VTE before pregnancy, prophylaxis might be decided for each individual case, taking into consideration all risk factors. In women with the FII mutation alone, the low risk may not justify prophylaxis in the absence of previous VTE. In post partum, prophylaxis is indicated in all cases.
No takes yet. Share an insight, caveat, or question.
Samama et al. (2003) conducted a cohort in Pregnancy-associated venous thromboembolism (VTE) (n=129). Combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210A mutation vs. Heterozygous FII mutation alone was evaluated on Venous thromboembolism (VTE) (RR 2.9, 95% CI 1.4-5.9, p=0.003). Combined heterozygous FVL and FII 20210A mutation was associated with a higher risk of pregnancy-associated VTE compared to FII mutation alone.
Synapse has enriched 10 related papers. Consider them for comparative context: